Establishment of Irinotecan resistant LIM 1215 cell line and identification of gene expression changes for Irinotecan resistance as well as discovering potential second line drugs reverting Irinotecan resistance

Date

2024-8-23

Author

Dilber, Tuğçe

Metadata

Show full item record

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Item Usage Stats

62
views

1
downloads

Cite This

Colorectal cancer (CRC) is the third most common cancer type worldwide. It is expected to have more than 2.2 million new cases and 1.1 million deaths by 2030 in the World. Irinotecan, a topoisomerase I inhibitor, is one of the widely used drugs in clinic for the treatment of Colorectal cancer (CRC) patients. Despite its efficacy, CRC patients frequently develop resistance against Irinotecan which leads to the treatment failure. The aim of this thesis is to investigate the underlying mechanisms of Irinotecan resistance in the LIM 1215 cell line, where acquired resistance was induced in vitro, as well as to identify potential second-line therapeutics that can revert the drug resistance. For this purpose, Irinotecan resistant Lim 1215 cell line divided into two groups: one group continued to be exposed to Irinotecan, while the other group was not exposed to Irinotecan. The transcriptomic changes and secondary drug sensitivities were analysed for both groups to improve treatment strategies for CRC patients with Irinotecan resistance.

Subject Keywords

Colorectal cancer, Drug resistance, Drug screening

URI

https://hdl.handle.net/11511/111484

Collections

Graduate School of Natural and Applied Sciences, Thesis